Table 1.

Antigens targeted by CARs

Target antigenAssociated malignancyReceptor type (other specificity)In vivo studiesReferences
α-Folate receptorOvarian cancerscFv-FcεRIγPhase I(1)
Epithelial cancersscFv-41BB-CD3-ζ+(2)
CAIXRenal cell carcinomascFv-CD4- FcεRIγPhase I(3–5)
Renal cell carcinomaG250-FceRIy(6–8)
CD19B-cell malignanciesscFv-CD3-ζ (EBV)(9)
B-cell malignanciesscFv-CD3-ζ+(10, 11)
B cell malignanciesscFv-CD28-CD3-ζ+(12–16)
Refractory follicular lymphomascFv-CD3-ζPhase I(17, 18)
B-cell malignanciesscFv-CD28-CD3-ζ+(19–22)
ALLscFv-41BB-CD3-ζ(23)
ALLscFv-41BB-CD3-ζ+(24)
B-cell malignanciesscFv-CD3-ζ (Influenza MP-1)+(25)
B-cell malignanciesscFv-CD3-ζ (VZV)(26)
ALLFMC63-CD28-41BB-CD3-ζ+, −(27–29)
B-cell malignanciesFMC63-41BB-CD3-ζ+(30)
Follicular lymphomaFMC63-CD28-CD3-ζNCT00924326(31)
B-cell malignanciesFMC63-CD28-CD3-ζNCT00924326(32)
CLLand ALLSJ25C1-CD28-CD3-ζ(NCT00466531 NCT01044069)(33)
CLLFMC63-41BB-CD3-ζNCT01029366(34, 35)
LymphomascFv-CD3-ζ + scFv-CD28-CD3-ζPhase I(36)
CD20LymphomasscFv-CD28-CD3-ζ(37)
B-cell malignanciesscFv-CD4-CD3-ζ(38)
B-cell lymphomasscFv-CD3-ζ(39,40)
Mantle cell lymphoma and indolent B-cell lymphomasscFv-CD28-41BB-CD3-ζNCT00621452(41,42)
CD22B-cell malignanciesscFV-CD4-CD3-ζ(38)
CD23CLLscFv-CD28-CD3-ζ+(43)
CD24Pancreatic adenocarcinomascFv- CD28-FcεRIy+(44)
CD30LymphomasscFv-FcεRIy(45)
Hodgkin lymphomascFv-CD3-ζ (EBV)+(46)
scFv-CD28-CD3-ζ (EBV)+(47)
CD33AMLscFv-CD28-CD3-ζ(48)
cFv-41BB-CD3-ζ
scFv-CD28-CD3-ζ (EBV)+(49)
CD38Non-Hodgkin lymphomascFv-41BB-CD3-ζ+(50)
CD44v7/8Cervical carcinomascFv-CD8-CD3-ζ+(51)
CEAColorectal cancerscFv-CD3-ζ+(52–56)
scFv-FcεRIy+(55,57)
scFv-CD3ε(58)
scFv-CD28-CD3-ζ(59)
scFv-CD28-CD3-ζ+(60,61)
EGFRvIIIGlioblastomascFv-CD28-41BB-CD3-ζNCT01454596(62)
EGP-2Multiple malignanciesscFv-CD3-ζ(63)
scFv-FcεRIy(63,64)
EGP-40Colorectal cancerscFv-FcεRIy(65)
EphA2GlioblastomascFv-CD28-CD3-ζ+(66)
Erb-B2Breast cancer and othersscFv-CD28-CD3-ζ+(67,68)
scFv-CD28-CD3-ζ (Influenza)+(69)
scFv-CD28mut.-CD3-ζ+(70)
Prostate cancer, colon cancerscFv-FcεRIy+(71)
(72)
Various tumorsscFv-CD28-41BB- CD3-ζ+(73,74)
Erb-B 2,3,4Breast cancer and othersHeregulin-CD3-ζ(75, 76)
scFv-CD3-ζ+(77)
FBPOvarian cancerscFv-FcεRIy+(78–80)
Ovarian cancerscFv-FcεRIy (alloantigen)+(81)
Fetal acethylcholine receptorRhabdomyosarcomascFv-CD3-ζ(82)
GD2Neuroblastoma, melanomascFv-CD3-ζ(9,10)
scFv-CD3-ζNCT00085930(83, 84)
scFv-CD28-OX40-CD3-ζ−, +(74,85,86)
scFv-CD3-ζ (VZV)(26)
Ewing sarcomascFv-CD28-CD3-ζ+(87)
GD3MelanomascFv-CD3-ζ, ScFv-CD3ε(88)
scFv-CD28-CD3-ζ+(89)
HER2MedulloblastomascFv-CD3-ζ+(90)
scFv-CD28-CD3-ζ+(91)
Pancreatic adenocarcinomascFv-CD28-41BB-CD3-ζ+(44)
GlioblastomaPhase I(92)
OsteosarcomascFv-CD28-CD3-ζ+(93)
Ovarian cancerscFv-CD28-CD3-ζ+(94)
HMW-MAAMelanomascFv-CD3-ζ, ScFv-CD28-CD3-ζ(95)
IL-11RαOsteosarcomascFv-CD28-CD3-ζ+(96)
IL-13Rα2GliomaIL-13-CD28-4-1BB-CD3-ζ+(97)
GlioblastomaIL-13-CD3-ζ+(98, 99)
MedulloblastomaIL-13-CD3-ζ+(100)
KDRTumor neovasculaturescFv-FcεRIy(101)
κ-light chainB-cell malignancies (B-NHL, CLL)scFv-CD3-ζ+(102)
scFv-CD28-CD3-ζ+(102)
Lewis YVarious carcinomasscFv-FcεRIy(103)
Epithelial-derived tumorsscFv-CD28-CD3-ζ+(104–106)
L1-cell adhesion moleculeNeuroblastomascFv-CD3-ζPhase I(107, 108)
MAGE-A1MelanomascFV-CD4-FcεRIy(109)
scFV-CD28-FcεRIy
MesothelinMesotheliomascFv-41BB-CD3-ζ+(73,110,111)
Murine CMV infected cellsMurine CMVLy49H-CD3-ζ+(112)
MUC1Breast and ovarian cancerscFV-CD28-OX40-CD3-ζ+(113, 114)
MUC16Ovarian cancerscFV-CD28-CD3-ζ(115)
NKG2D LigandsMyeloma, ovarian, and other tumorsNKG2D-CD3-ζ+(116–121)
NY-ESO-1 (157–165)Multiple myelomascFv-CD28-CD3-ζ+(122)
Oncofetal antigen (h5T4)Various tumorsscFV-CD3-ζ (vaccination)+(123)
PSCAProstate carcinoma7F5-β2-CD3-ζ(124)
scFv-CD3-ζ(125)
PSMAProstate cancer/tumor vasculaturescFv-CD3-ζ+(126, 127)
Prostate/tumor vasculaturescFv-CD28-CD3-ζ(128)
scFv-CD3-ζ+(129)
ROR1B-CLL and mantle cell lymphomascFv-CD28-CD3-ζ+(130)
Targeting via mAb IgEVarious tumorsFcεRI-CD28-CD3-ζ+(131)
TAG-72AdenocarcinomasscFv-CD3-ζ+(132, 133)
VEGF-R2Tumor neovasculaturescFv-CD3-ζ(134)
Biotinylated moleculesVarious tumors, ovarian cancerBBIR-z/CD28z+(135)

NOTE: This table lists the target antigens and corresponding CARs that have been reported to date. The reference list for the table can be found in Supplementary item 1.

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; EBV, Epstein-Barr virus; EGFR, epidermal growth factor receptor; HMW-MAA, high-molecular-weight melanoma-associated antigen; mAb, monoclonal antibody; NHL, non-Hodgkin lymphoma; PSCA, prostate stem cell antigen; PSMA, prostate-specific membrane antigen.